Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

6
results for

"Immunohistochemistry"

Article category

Keywords

Publication year

"Immunohistochemistry"

Review

Hepatic neoplasm

Pathologic differential diagnosis of metastatic carcinoma in the liver
Jeong Hwan Park, Jung Ho Kim
Clin Mol Hepatol 2019;25(1):12-20.
Published online October 5, 2018
DOI: https://doi.org/10.3350/cmh.2018.0067
The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the metastasis of carcinomas to the liver is relatively common and frequently encountered in clinical settings. Representative carcinomas that frequently metastasize to the liver include colorectal carcinoma, breast carcinoma, neuroendocrine tumors, lung carcinoma, and gastric carcinoma. The diagnostic confirmation of suspected metastatic lesions in the liver is generally achieved through a histopathologic examination of biopsy tissues. Although morphology is the most important feature for a pathologic differential diagnosis of metastatic carcinomas, immunohistochemical studies facilitate the differentiation of metastatic carcinoma origins and subtypes. Useful immunohistochemical markers for the differential diagnosis of metastatic carcinomas in the liver include cytokeratins (CK7, CK19, and CK20), neuroendocrine markers (CD56, synaptophysin, and chromogranin A), and tissue-specific markers (CDX2, SATB2, TTF-1, GCDFP-15, mammaglobin, etc.). Here, we provide a brief review about the pathologic differential diagnosis of major metastatic carcinomas in the liver.

Citations

Citations to this article as recorded by  Crossref logo
  • Endoscopic ultrasound‐guided tissue acquisition for focal liver lesions in patients with a history of multiple primary malignant neoplasms
    Yuichi Takano, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Fumitaka Niiya, Fumiya Nishimoto, Naotaka Maruoka, Tatsuya Yamagami, Masatsugu Nagahama
    DEN Open.2025;[Epub]     CrossRef
  • Machine learning-assisted pattern recognition and imaging of multiplexed cancer cells via a porphyrin-embedded dendrimer array
    Jiabao Hu, Weiwei Ni, Mengting Han, Yunzhen Zhan, Fei Li, Hui Huang, Jinsong Han
    Journal of Materials Chemistry B.2025; 13(1): 207.     CrossRef
  • Molecular subtypes of intrahepatic cholangiocarcinoma
    Alessandro De Santis, Lei Zhu, Jianxin Tao, Christoph Reißfelder, Sebastian Schölch
    Trends in Molecular Medicine.2025; 31(8): 755.     CrossRef
  • Biliary Adenofibroma and the Threat of Malignant Transformation
    Mohamed A. Youssef, Joseph Gosnell, Heather L. Stevenson
    International Journal of Surgical Pathology.2025; 33(7): 1658.     CrossRef
  • Long-term SiNPs exposure induced genetic instability and malignant transformation via SQSTM1/p62-mediated autophagy dysfunction in lungs
    Kanglin Yan, Yuexiao Ma, Xuemin Shi, Chen Liang, Ruiyang Ding, Zhiwei Sun, Junchao Duan
    Materials Today Bio.2025; 33: 101972.     CrossRef
  • Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives
    Jianfeng Zhou, Yuan Sui, Zhihua Chen
    iScience.2025; 28(7): 112902.     CrossRef
  • Quantitative Assessment of Peritumoral Stiffness Using Shell Elastography Enhances the Differentiation of Hepatocellular Carcinoma From Metastatic Liver Carcinoma
    Yang Li, Zhaoyu Wu, Min Zhu, Banban Wu, Yibin Wang
    Journal of Ultrasound in Medicine.2025;[Epub]     CrossRef
  • Discovery of novel DNA methylation biomarker panels for the diagnosis and differentiation between common adenocarcinomas and their liver metastases
    Tina Draškovič, Nina Hauptman
    Scientific Reports.2024;[Epub]     CrossRef
  • Identifying primary tumor site of origin for liver metastases via a combination of handcrafted and deep learning features
    Chuheng Chen, Cheng Lu, Vidya Viswanathan, Brandon Maveal, Bhunesh Maheshwari, Joseph Willis, Anant Madabhushi
    The Journal of Pathology: Clinical Research.2024;[Epub]     CrossRef
  • Advancing Differentiation of Hepatic Metastases in Malignant Melanoma through Dual-Energy Computed Tomography Rho/Z Maps
    Ibrahim Yel, Vitali Koch, Leon D. Gruenewald, Scherwin Mahmoudi, Leona S. Alizadeh, Aynur Goekduman, Katrin Eichler, Thomas J. Vogl, Mirela Dimitrova, Christian Booz
    Diagnostics.2024; 14(7): 742.     CrossRef
  • Exploring the potential of drug repurposing for liver diseases: A comprehensive study
    Fares E.M. Ali, Mustafa Ahmed Abdel-Reheim, Emad H.M. Hassanein, Mostafa K. Abd El-Aziz, Hanan S. Althagafy, Khalid S.A. Badran
    Life Sciences.2024; 347: 122642.     CrossRef
  • Impact of immunotherapy on liver metastasis
    Zhuo Fu, Ming-Wei Wang, Ya-Hui Liu, Yan Jiao
    World Journal of Gastrointestinal Surgery.2024; 16(7): 1969.     CrossRef
  • An audit of metastatic tumors to the liver highlighting the spectrum of differential diagnosis: A retrospective study from a tertiary cancer center in North India
    Neha Singh, Ipsita Dhal, Kirti Rajput, Zachariah Chowdhury, Shashikant Patne, Parul Tripathi, Swapnil Patel, Mayank Tripathi, Durgatosh Pandey, Bipinesh Sansar
    Cancer Research, Statistics, and Treatment.2024; 7(2): 149.     CrossRef
  • Automated diagnosis and classification of liver cancers using deep learning techniques: a systematic review
    Sarthak Grover, Surbhi Gupta
    Discover Applied Sciences.2024;[Epub]     CrossRef
  • Benefits and drawbacks of radiofrequency ablation via percutaneous or minimally invasive surgery for treating hepatocellular carcinoma
    Ching-Lung Hsieh, Cheng-Ming Peng, Chun-Wen Chen, Chang-Hsien Liu, Chih-Tao Teng, Yi-Jui Liu
    World Journal of Gastrointestinal Surgery.2024; 16(11): 3400.     CrossRef
  • Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma
    Yeon Seung Chung, Youngsic Jeon, Jeong Eun Yoo, Taek Chung, Hyang Joo Ryu, Hyunki Kim, Hyungjin Rhee, Young Nyun Park
    Hepatology International.2023; 17(1): 77.     CrossRef
  • Una causa inusual de fallo hepático fulminante: infiltración metastásica por carcinoma ductal infiltrante de mama
    Francisco Javier Pardilla Moraleda, Rosario Serrano Pardo, Lourdes del Campo del Val, Luisa García-Buey
    Gastroenterología y Hepatología.2023; 46(9): 710.     CrossRef
  • Laparoscopic Hepatectomy for Hepatocellular Carcinoma
    Qiyu Qiu
    Highlights in Science, Engineering and Technology.2023; 30: 12.     CrossRef
  • EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
    Domenico Alvaro, Gregory J. Gores, Joël Walicki, Cesare Hassan, Gonzalo Sapisochin, Mina Komuta, Alejandro Forner, Juan W. Valle, Andrea Laghi, Sumera I. Ilyas, Joong-Won Park, Robin K. Kelley, Maria Reig, Bruno Sangro
    Journal of Hepatology.2023; 79(1): 181.     CrossRef
  • Breast mass as the first sign of metastasis from rectal carcinoma: a case report and review of the literature
    Jiawei Xu, Chao Liu, Chengdong Yu, Tenghua Yu, Fan Fan, Xiaofang Zhang, Chuansheng Huang, Wen Chen, Zhengkui Sun, Meng Zhou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Carcinoma of unknown primary (CUP): an update for histopathologists
    Katie Beauchamp, Bruce Moran, Timothy O’Brien, Donal Brennan, John Crown, Kieran Sheahan, Maura Bríd Cotter
    Cancer and Metastasis Reviews.2023; 42(4): 1189.     CrossRef
  • Implementation of deep learning in liver pathology optimizes diagnosis of benign lesions and adenocarcinoma metastasis
    Mark Kriegsmann, Katharina Kriegsmann, Georg Steinbuss, Christiane Zgorzelski, Thomas Albrecht, Stefan Heinrich, Stefan Farkas, Wilfried Roth, Hien Dang, Anne Hausen, Matthias M. Gaida
    Clinical and Translational Medicine.2023;[Epub]     CrossRef
  • An unusual cause of fulminant hepatic failure: Metastatic infiltration by infiltrating ductal carcinoma of the breast
    Francisco Javier Pardilla Moraleda, Rosario Serrano Pardo, Lourdes del Campo del Val, Luisa García-Buey
    Gastroenterología y Hepatología (English Edition).2023; 46(9): 710.     CrossRef
  • Deep Learning for the Pathologic Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer
    Hyun-Jong Jang, Jai-Hyang Go, Younghoon Kim, Sung Hak Lee
    Cancers.2023; 15(22): 5389.     CrossRef
  • Primäre und sekundäre Lebertumore
    Nabeel Mansour, Max Seidensticker, Maurice M. Heimer
    Angewandte Nuklearmedizin.2023; 46(04): 323.     CrossRef
  • Liver metastasis of breast carcinoma: An unusual presentation and growth pattern
    Mine Özşen, Nesrin Uğraş, Ömer Yerci, Adem Deligönül
    Indian Journal of Pathology and Microbiology.2023; 66(4): 877.     CrossRef
  • Metastatic Liver Tumors in Surgical Pathology: Impact of Contemporary Diagnostic and Therapeutic Paradigms in a Tertiary Care Center
    Ayşe Armutlu, Omer Saeed, Romil Saxena
    International Journal of Surgical Pathology.2022; 30(2): 138.     CrossRef
  • Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
    Taek Chung, Young Nyun Park
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand
    Supinda Koonmee, Sakkarn Sangkhamanon, Piyapharom Intarawichian, Chaiwat Aphivatanasiri, Waritta Kunprom, Prakasit Sa-ngiamwibool, Suwit Balthaisong, Chitsakul Phuyao, Piya Prajumwongs, Reza Alaghehbandan, Malinee Thanee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review
    Romans Uljanovs, Stanislavs Sinkarevs, Boriss Strumfs, Liga Vidusa, Kristine Merkurjeva, Ilze Strumfa
    International Journal of Molecular Sciences.2022; 23(13): 6981.     CrossRef
  • Oesophageal and gastric cancers: From epidemiology to modern treatment
    Nikola Milošević, Srđan Milanović
    Glasnik javnog zdravlja.2022; 96(2): 203.     CrossRef
  • Diagnosis of the Primary Tumor Site in the Case of Liver Metastatic Carcinoma
    Mercedes Malone, Christopher Bray, Xiaolong Sean Liu
    Cureus.2022;[Epub]     CrossRef
  • Probe electrospray ionization mass spectrometry‐based rapid diagnosis of liver tumors
    Hiroyuki Hakoda, Sho Kiritani, Takashi Kokudo, Kentaro Yoshimura, Tomohiko Iwano, Meguri Tanimoto, Takeaki Ishizawa, Junichi Arita, Nobuhisa Akamatsu, Junichi Kaneko, Sen Takeda, Kiyoshi Hasegawa
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2182.     CrossRef
  • Case report: Rare isolated cystic hepatic metastasis of a patient with squamous cell lung carcinoma history and the prognosis
    Chunbao Liu, Xiaomin Chen, Hang Su, Liang Xia, Diyu Lu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments
    Kumi Ozaki, Shohei Higuchi, Hirohiko Kimura, Toshifumi Gabata
    RadioGraphics.2022; 42(7): 1994.     CrossRef
  • Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report
    Yiying Tao, Lei Tang, Li Zuo, Yue Ma, Fengchun Zhang, Yingchun Xu
    Oncology Letters.2022;[Epub]     CrossRef
  • Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection
    Aleksandar Bogdanovic, Jovana Despotovic, Danijel Galun, Nemanja Bidzic, Aleksandra Nikolic, Jovana Rosic, Zoran Krivokapic
    Cancer Management and Research.2021; Volume 13: 163.     CrossRef
  • Preoperative classification of primary and metastatic liver cancer via machine learning-based ultrasound radiomics
    Bing Mao, Jingdong Ma, Shaobo Duan, Yuwei Xia, Yaru Tao, Lianzhong Zhang
    European Radiology.2021; 31(7): 4576.     CrossRef
  • Real-time lipid patterns to classify viable and necrotic liver tumors
    Pierre-Maxence Vaysse, Heike I. Grabsch, Mari F.C.M. van den Hout, Marc H.A. Bemelmans, Ron M.A. Heeren, Steven W.M. Olde Damink, Tiffany Porta Siegel
    Laboratory Investigation.2021; 101(3): 381.     CrossRef
  • Self-organization in cancer: Implications for histopathology, cancer cell biology, and metastasis
    Senthil K. Muthuswamy
    Cancer Cell.2021; 39(4): 443.     CrossRef
  • Cervical lymph node enlargement as the initial manifestation of rectal cancer
    Tong-Hui Xie, Peng Su, Jian-Guo Hong, Hui Zhang
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer
    Mizelle D’Silva, Jai Young Cho, Ho-Seong Han, Taupyk Yerlan, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases
    Caiyuan Zhang, Aileen O'Shea, Chiara Anna Parente, Barbara Juarez Amorim, Peter Caravan, Christina R. Ferrone, Lawrence S. Blaszkowsky, Andrea Soricelli, Marco Salvatore, David Groshar, Hanna Bernstine, Liran Domachevsky, Lina Garcia Canamaque, Lale Umutl
    Investigative Radiology.2021; 56(10): 621.     CrossRef
  • Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
    Anne Menz, Rifka Bauer, Martina Kluth, Clara Marie von Bargen, Natalia Gorbokon, Florian Viehweger, Maximilian Lennartz, Cosima Völkl, Christoph Fraune, Ria Uhlig, Claudia Hube-Magg, Noémi De Wispelaere, Sarah Minner, Guido Sauter, Simon Kind, Ronald Simo
    Human Pathology.2021; 115: 19.     CrossRef
  • Cholangiocarcinoma
    Samantha Sarcognato, Diana Sacchi, Matteo Fassan, Luca Fabris, Massimiliano Cadamuro, Giacomo Zanus, Ivana Cataldo, Paola Capelli, Francesca Baciorri, Matilde Cacciatore, Maria Guido
    Pathologica.2021; 113(3): 158.     CrossRef
  • Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing
    Jun-Kyu Kang, Sunghoon Heo, Hwang-Phill Kim, Sang-Hyun Song, Hongseok Yun, Sae-Won Han, Gyeong Hoon Kang, Duhee Bang, Tae-You Kim, Alvaro Galli
    PLOS ONE.2020; 15(5): e0232754.     CrossRef
  • Metastatic breast cancer presenting as acute liver injury: diagnostic dilemma in the setting of suspected hemochromatosis
    Raguraj Chandradevan, Hironobu Takeda, Benjamin Hayes, Kalli Faulkner, Matthew Darrow
    Oxford Medical Case Reports.2020;[Epub]     CrossRef
  • Critical steps to tumor metastasis: alterations of tumor microenvironment and extracellular matrix in the formation of pre-metastatic and metastatic niche
    Jianan Zhuyan, Mingyu Chen, Tianhao Zhu, Xunxia Bao, Timing Zhen, Kaichen Xing, Qiubo Wang, Sibo Zhu
    Cell & Bioscience.2020;[Epub]     CrossRef
  • Colorectal liver metastases: radiopathological correlation
    Luisa Paulatto, Marco Dioguardi Burgio, Riccardo Sartoris, Aurélie Beaufrère, François Cauchy, Valérie Paradis, Valérie Vilgrain, Maxime Ronot
    Insights into Imaging.2020;[Epub]     CrossRef
  • Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging
    Domenico Alvaro, Cesare Hassan, Vincenzo Cardinale, Guido Carpino, Luca Fabris, Enrico Gringeri, Vincenza Granata, Massimiliano Mutignani, Helen Morement, Felice Giuliante, Alfredo Guglielmi, Lorenzo Ridola, Marco Marzioni, Gianluca Grazi, Maria Guido, Em
    Digestive and Liver Disease.2020; 52(11): 1282.     CrossRef
  • Hepatocellular carcinomas can be Special AT-rich sequence-binding protein 2 positive: an important diagnostic pitfall
    Whayoung Lee, Xiaodong Li, Vishal S. Chandan
    Human Pathology.2020; 105: 47.     CrossRef
  • Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans
    Wei Yu, Sanjit K. Roy, Yiming Ma, Thomas A. LaVeist, Sharmila Shankar, Rakesh K. Srivastava
    Journal of Cellular and Molecular Medicine.2019; 23(12): 7999.     CrossRef
  • 34,604 View
  • 1,178 Download
  • 50 Web of Science
  • Crossref
Original Articles

Hepatic neoplasm

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eun Sil Yu, Ki Hun Kim, Seung-Mi Kim, Tae Won Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2015;21(1):60-70.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.60
Background/Aims

Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications.

Methods

Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis.

Results

FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set.

Conclusions

FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Mas
    Scientific Reports.2024;[Epub]     CrossRef
  • Evolving therapeutic landscape of advanced hepatocellular carcinoma
    Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, René Bernards, Wenxin Qin, Cun Wang
    Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 203.     CrossRef
  • Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice
    Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka
    Liver Cancer.2023; 12(1): 57.     CrossRef
  • Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients
    Walizeb Khan, Washaakh Ahmad, Anwar M. Hashem, Shadi Zakai, Shafiul Haque, Muhammad Faraz Arshad Malik, Steve Harakeh, Farhan Haq
    Journal of Clinical Medicine.2022; 11(11): 3093.     CrossRef
  • Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy
    Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2022; 14(19): 4647.     CrossRef
  • AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Yun Feng, Dan Zhang, Gaixia He, Yaping Liu, Yan Zhao, Xiaoyang Ren, Huanhuan Sun, Guifang Lu, Zhiyong Zhang, Li Ren, Yan Yin, Hongxia Li, Shuixiang He
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(18): 3107.     CrossRef
  • Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Matthias Ocker
    World Journal of Gastroenterology.2020; 26(3): 279.     CrossRef
  • Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
    Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon
    International Journal of Molecular Sciences.2020; 21(2): 472.     CrossRef
  • Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
    Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satos
    Cancers.2020; 12(2): 293.     CrossRef
  • First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin
    Targeted Oncology.2019; 14(5): 591.     CrossRef
  • The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma
    Prachi Rana, John Haydek, Anjana Pillai
    Current Hepatology Reports.2019; 18(4): 371.     CrossRef
  • Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
    Oleg V. Grinchuk, Surya P. Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce Kah‐Hoe Chow, Vladamir A. Kuznetsov
    Molecular Oncology.2018; 12(1): 89.     CrossRef
  • Molecular therapies and precision medicine for hepatocellular carcinoma
    Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn
    Nature Reviews Clinical Oncology.2018; 15(10): 599.     CrossRef
  • Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
    Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong
    Cytokine.2017; 95: 118.     CrossRef
  • Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis
    Gang Liu, Disheng Xiong, Rui Xiao, Zhengjie Huang
    Tumor Biology.2017; 39(6): 101042831770742.     CrossRef
  • Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
    Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon
    Digestive Diseases and Sciences.2016; 61(9): 2568.     CrossRef
  • 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma
    Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang, Meng Xu
    World Journal of Gastroenterology.2016; 22(21): 5033.     CrossRef
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
    Wenya Zhou, Xiaoling Du, Fengju Song, Hong Zheng, Kexin Chen, Wei Zhang, Jilong Yang
    Oncotarget.2016; 7(16): 22234.     CrossRef
  • MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression
    Ming-Hua Hu, Chen-Yang Ma, Xiao-Ming Wang, Chen-Dong Ye, Guang-Xian Zhang, Lin Chen, Jin-Guo Wang
    Oncotarget.2016; 7(41): 66922.     CrossRef
  • NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report
    E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N.
    Biopolymers and Cell.2015; 31(6): 436.     CrossRef
  • 11,453 View
  • 135 Download
  • 21 Web of Science
  • Crossref

Hepatic neoplasm

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
Jee Eun Yang, Eunji Park, Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eunsil Yu, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2014;20(1):28-37.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.28
Background/Aims

The role of prostaglandin E2 (PGE2) in the modulation of cell growth is well established in colorectal cancer. The aim of this study was to elucidate the significance of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) down-regulation on the prognosis of hepatocellular carcinoma (HCC) patients.

Methods

The expression of 15-PGDH in HCC cell lines and resected HCC tissues was investigated, and the correlation between 15-PGDH expression and HCC cell-line proliferation and patient survival was explored.

Results

The interleukin-1-β-induced suppression of 15-PGDH did not change the proliferation of PLC and Huh-7 cells in the MTS [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The induction of 15-PGDH by transfection in HepG2 cells without baseline 15-PGDH expression was suppressed at day 2 of proliferation compared with empty-vector transfection, but there was no difference at day 3. Among the 153 patients who received curative HCC resection between 2003 and 2004 at our institution, 15-PGDH expression was observed in resected HCC tissues in 56 (36.6%), but the 5-year survival rate did not differ from that of the remaining 97 non-15-PGDH-expressing patients (57.1% vs 59.8%; P=0.93). Among 50 patients who exhibited baseline 15-PGDH expression in adjacent nontumor liver tissues, 28 (56%) exhibited a reduction in 15-PGDH expression score in HCC tissues, and there was a trend toward fewer long-term survivors compared with the remaining 22 with the same or increment in their 15-PGDH expression score in HCC tissues.

Conclusions

The prognostic significance of 15-PGDH down-regulation in HCC was not established in this study. However, maintenance of 15-PGDH expression could be a potential therapeutic target for a subgroup of HCC patients with baseline 15-PGDH expression in adjacent nontumor liver tissue.

Citations

Citations to this article as recorded by  Crossref logo
  • The tumor suppressor role and epigenetic regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in cancer and tumor microenvironment (TME)
    SubbaRao V. Tulimilli, Medha Karnik, Anjali Devi S. Bettadapura, Olga A. Sukocheva, Edmund Tse, Gowthamarajan Kuppusamy, Suma M. Natraj, SubbaRao V. Madhunapantula
    Pharmacology & Therapeutics.2025; 268: 108826.     CrossRef
  • 15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells
    Jeong-Eun Lee, Xiancai Zhong, Ja-Young Lee, Young-Joon Surh, Hye-Kyung Na
    Archives of Biochemistry and Biophysics.2020; 679: 108162.     CrossRef
  • The prostanoid pathway contains potential prognostic markers for glioblastoma
    Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
    Prostaglandins & Other Lipid Mediators.2018; 137: 52.     CrossRef
  • 10,521 View
  • 70 Download
  • 3 Web of Science
  • Crossref
Clinicopathologic significance of the expression of Snail in hepatocellular carcinoma
Hyun Young Woo, Ae Lyoung Min, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon, Chan Kwon Jung
Korean J Hepatol 2011;17(1):12-18.
Published online March 21, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.1.12
Background/Aims

E-cadherin is involved in intercellular binding and cellular polarity formation. Snail is a key regulator of the epithelial-mesenchymal transition and is closely associated with tumor invasiveness due to its ability to suppress E-cadherin expression. We investigated the expressions of E-cadherin and Snail in hepatocellular carcinoma (HCC) tissue to determine the clinical significance of these proteins in HCC.

Methods

Immunohistochemistry was used to examine the expressions of E-cadherin and Snail in resected tissues from 59 patients diagnosed with HCC. We also evaluated the relationship between the expressions of these two molecules in HCC tissue and clinicopathologic factors in the patients.

Results

Immunohistochemistry showed that Snail was stained in 20.3% of the HCC tissues and 3.4% of noncancerous tissues. Snail was not stained in the area of E-cadherin expression. The expression of Snail in the HCC tissue was associated with poorly differentiated HCC (P=0.028). The expression of Snail without E-cadherin staining in HCC tissue was significantly associated with postoperative HCC recurrence (P=0.013).

Conclusions

The expression of Snail in HCC tissue was associated with decreased expression of E-cadherin and poorly differentiated HCC. The expression of Snail without E-cadherin staining in HCC was associated with postoperative recurrence.

Citations

Citations to this article as recorded by  Crossref logo
  • Low-dose cisplatin exposure and SNAIL, Vimentin, E-cadherin expression in HEPG2 cell line
    Yaprak Dönmez Çakıl, Zeynep Akbulut, Ranan Gülhan Aktaş, Zeynep Gunes Ozunal
    International Journal of Medical and Surgical Sciences.2022; : 1.     CrossRef
  • Germline Variants and Genetic Interactions of Several EMT Regulatory Genes Increase the Risk of HBV-Related Hepatocellular Carcinoma
    Wen-Xuan Liu, Lei Yang, Hui-Min Yan, Li-Na Yan, Xiao-Lin Zhang, Ning Ma, Long-Mei Tang, Xia Gao, Dian-Wu Liu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer
    Takuo Ogihara, Kenta Mizoi, Hiroki Kamioka, Kentaro Yano
    Cancers.2020; 12(11): 3352.     CrossRef
  • Hepatitis C virus core protein increases Snail expression and induces epithelial–mesenchymal transition through the signal transducer and activator of transcription 3 pathway in hepatoma cells
    Jia‐Jia Zhou, Zhe Meng, Xiao‐Yu He, Di Cheng, Hui‐Lin Ye, Xiao‐Geng Deng, Ru‐Fu Chen
    Hepatology Research.2017; 47(6): 574.     CrossRef
  • Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells
    Takumi Tomono, Kentaro Yano, Takuo Ogihara
    Journal of Pharmaceutical Sciences.2017; 106(9): 2642.     CrossRef
  • Clinicopathologic Correlations of E-cadherin and Prrx-1 Expression Loss in Hepatocellular Carcinoma
    Kijong Yi, Hyunsung Kim, Yumin Chung, Hyein Ahn, Jongmin Sim, Young Chan Wi, Ju Yeon Pyo, Young-Soo Song, Seung Sam Paik, Young-Ha Oh
    Journal of Pathology and Translational Medicine.2016; 50(5): 327.     CrossRef
  • Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery
    MINGSHENG HUANG, LONG WANG, JUNWEI CHEN, MINGJUN BAI, CHUREN ZHOU, SUJUAN LIU, QU LIN
    International Journal of Oncology.2016; 48(5): 2144.     CrossRef
  • Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling
    Xin Yin, Bo-Heng Zhang, Su-Su Zheng, Dong-Mei Gao, Shuang-Jian Qiu, Wei-Zhong Wu, Zheng-Gang Ren
    Journal of Hematology & Oncology.2015;[Epub]     CrossRef
  • Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival
    Zhao-Shan Niu
    World Journal of Hepatology.2015; 7(1): 7.     CrossRef
  • Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells
    Min Zhang, Hai Zhang, Shanyu Cheng, Dengcai Zhang, Yan Xu, Xiaoming Bai, Shukai Xia, Li Zhang, Juan Ma, Mingzhan Du, Yipin Wang, Jie Wang, Meng Chen, Jing Leng
    Tumor Biology.2014; 35(7): 7135.     CrossRef
  • Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention
    Samantha Kaufhold, Benjamin Bonavida
    Journal of Experimental & Clinical Cancer Research.2014;[Epub]     CrossRef
  • Prognostic Significance of E-Cadherin Expression in Hepatocellular Carcinoma: A Meta-Analysis
    Jiang Chen, Jie Zhao, Rui Ma, Hui Lin, Xiao Liang, Xiujun Cai, Kwan Man
    PLoS ONE.2014; 9(8): e103952.     CrossRef
  • Snail-Regulated MiR-375 Inhibits Migration and Invasion of Gastric Cancer Cells by Targeting JAK2
    Yanjun Xu, Juan Jin, Yiman Liu, Zhenxia Huang, Yujie Deng, Tao You, Tianhua Zhou, Jianmin Si, Wei Zhuo, Ming Tan
    PLoS ONE.2014; 9(7): e99516.     CrossRef
  • 9,852 View
  • 59 Download
  • Crossref
The Correlation Between The Histologic Activity and Fibrosis and The Distribution of Intrahepatic HBsAg and HBcAg in Patients With Chronic Hepatitis B
Kwang Bum Cho, M.D., Jung Ho Sohn, M.D., Kyung Sik Park, M.D., Du Young Kwon, M.D., Jae Seok Hwang, M.D., Jung Wook Hur, M.D., Sung Hoon Ahn, M.D., Soong Kuk Park, M.D., and Sang Pyo Kim, M.D.*
Korean J Hepatol 2001;7(4):401-412.
Background
/ Aims : The purpose of this study was to assess the correlation between histologic activity and fibrosis and the distribution of intrahepatic hepatitis B core antigen(HBcAg) and surface antigen(HBcAg ) inpatients with chronic hepatitis B . Methods : 141 patients(M:F=141:27) with biopsy-proven chronic hepatitis B ,abnormal liver function, and a positive HBV viral marker(serum HBeAg , serum HBV DNA) were enrolled. Results : HBcAg was expressed in 96 of 141 patoents(68.1%), n HBcAg in 23(16.3%), c HBcAg in 58(41.25), and n-c HBcAg in 15(10.6%). In the cases of HBsAg, 114 of 141 patients(80.9%) were expressed as c HBsAg, 2(1.4%) as m HBsAg, and 16(11,3%) as m-c HBsAg. The presence of intrahepatic HBcAg and HBsAg according to gudat`s calssification was not correlated with activity and fibrosis. But the groups with nuckear expression of HBcAg revealed less inflammatory activity (grade, p=0.003), and less fibrotic stage(p=0.002) than with cytoplasmic or no expression of HBcAg. HBsAg was not. Conclusion : These observations suggest that inflammatory activity and fibrosis of chronic hepatitis B are related to the presence of HBcAg in hepatocytes and the expression of HBcAg. This is a very important finding in hepatocytolysis. (Korean J Hepatol 2001;7 :401- 412)
  • 2,797 View
  • 18 Download
Expression Patterns of E - cadherin and β - catenin According to Clinicopathological Characteristics of Hepatocellular Carcinoma
Si Hyun Bae, M.D.1,4, Eun Sun Jung, M.D.2, Young Min Park, M.D.1,4, Jeong Won Jang, M.D.1,4, Jong Young Choi, M.D.1,4, Se Hyun Cho, M.D.1,4, Seung Kew Yoon, M.D.1,4, Byung Min Ahn, M.D.1,4, Sang Bok Cha, M.D.1,4, Kyu Won Chung, M.D.1,4, Hee Sik Sun, M.D.1,4, Doo Ho Park, M.D.1,4, Byung Kee Kim, M.D.2, Dong Goo Kim, M.D.3
Korean J Hepatol 2002;8(3):297-303.
Background/Aims
E-cadherin is involved in intercellular binding and cellular polarity formation. β-catenin plays a fundamental role in regulation of the E-cadherin cell adhesion complex. The abnormalities of the components of the complex may disrupt this adhesive function. We investigated the expression patterns of E-cadherin and β-catenin to determine the clinical significance of these proteins in hepatocellular carcinoma. Materials/Methods: Thirty-six hepaticellular carcinoma tissues and adjacent non-tumor specimens were analyzed. Subcellular distribution of E-cadherin and β-catenin was examined by immunohistochemistry staining. We evaluated the patterns of the expression, and investigated the relationship with the cause of HCC; level of AFP; TNM stage; tumor size; growth types; metastasis; differentiation grade of HCC; and presence of portal vein thrombosis. Results: Immunohistochemistry showed that all non-tumor tissues had membranous type staining of E-cadherin. All non-tumor tissues showed cytoplasmic type staining of β-catenin, but no β -catenin accumulation in nuclei was found. 58% (21/36) of HCC showed positive expression of E-cadherin in cytoplasmic membrane. The cytoplasmic expression of β-catenin in HCC was 83% (30/36); nuclear expression in 14% (5/36); and no staining in 3% (1/36). Nuclear β-catenin expression was observed in none (0/4) of the well-differentiated HCC; 17%(3/9) of moderate-differentiated HCC; and 17%(2/6) of poorly-differentiated HCC. There were no relationships between E-cadherin and β-catenin expression with other clinicopathologic factors. Conclusions: Loss of cytoplasmic staining of E-cadherin and nuclear accumulation of β-catenin were observed in HCC. Nuclear accumulation of β-catenin was not found in well differentiated HCC but was found in poorly differentiated HCC. (Korean J Hepatol 2002;8:297-303)
  • 3,249 View
  • 28 Download